Table 1
Summary of 25 randomized clinical studies and tvo drug-monitoring studies on the efficiency of Hypericum in the treatment of depression and anxiety.
| Authors year | No of cases | Total hypericin/day | Weeks | Target Parameters | Test preparation | Respons rate | Compared treatment | Resp. rate | Rating |
| Witte, 1995 | 97 | 0,5 mg x 2 | 6 | HAMD, D-S | Psychotonin | 79 % | Placebo | 56% | - |
| Ditzler, 1994 | 60 | 0,24 mg x 2 | 8 | D-S | Neurapas*** | 67% | Placebo | 33% | - |
| Albrecht, 1994 | 1060 | 0,3 mg x 3 | 4 | HAMD, D-S | Jarsin | 75% | None | - | - |
| Woelk, 1993 | 3250 | 0,9 mg x 3 | 4 | D-S | Jarsin 300 | 82% | None | - | - |
| Sommer,1993 | 105 | 0,9 mg x 3 | 4 | HAMD | Jarsin 300 | 67% | Placebo | 28% | 41 |
| Huebner,1993 | 40 | 0,9 mg x 3 | 4 | HAMD, B-L,CGI | Jarsin 300 | 70% | Placebo | 47% | 54 |
| Hänsgen, 1993 | 100 | 0,9 mg x 3 | 6 | HAMD, D-S, CGI, BEB | Jarsin 300 | 81% | Placebo | 26% | 55 |
| Vorbach, 1993 | 135 | 0,9 mg x 3 | 6 | HAMD, D-S, CGI | Jarsin 300 | 82% | Imipramin | 62% | 74 |
| Harrer, 1993 | 102 | 1 mg x 3 | 4 | HAMD, D-S, CGI | Jarsin 300 | 61% | Maprotilin, | 67% | 70 |
| Bergmann, 1993 | 76 | 0,25mg x3 | 6 | HAMD, Bf-S | Esbericum | 84% | Amitryptilin | 74% | 38 |
| Martinez, 1993 | 20 | 0,9 mg x 3 | 4 | HAMD, (SAD-patients) | Jarsin + 300 Lux | 60% | Jarsin + 3000Lux | 72% | 38 |
| König, 1993 | 112 | 0,5-1mg x 2 | 6 | Bf-S | Extract Z 90017 | 53% | Placebo | 53% | - |
| Lehrl, 1993 | 50 | 0,37 mg x 3 | 4 | HAMD, KAI | Jarsin | 42% | Placebo | 25% | 25 |
| Schmidt, 1993 | 65 | 0,37 mg x 3 | 6 | HAMD, Cognition | Jarsin | 67% | Placebo | 26.7% | - |
| Quandt, 1993 | 88 | 0,37 mg x 3 | 4 | HAMD | Psychotonin M | 70,7% | Placebo | 7,7% | 49 |
| Reh, 1992 | 50 | 0,5mg x 2 | 8 | HAMD | Neuroplant | 70% | Placebo | 45% | 55 |
| Osterheider, 1992 | 46 | 0,25mg x 2 | 8 | HAMD | Neuroplant | 0% | Placebo | 0% | 25 |
| Harrer, 1991 | 116 | 0.37 mg x 3 | 6 | HAMD, HAMA, D-S | Psychotonin | 75% | Placebo | 25% | 52 |
| Halama, 1991 | 50 | 0.3 mg x 3 | 4 | HAMD, B-L, CGI | Jarsin | 60% | Placebo | 12% | 55 |
| Werth, 1989 | 30 | 0,37 mg x 3 | 3,5 | HAMDafter amputation | Psychotonin M | 73% | Imipramin | 60% | 43 |
| Schmidt, 1989 | 40 | 0,37 mg x 3 | 4 | HAMD , STAI | Psychotonin M | 65% | Placebo | 33% | - |
| Kniebel, 1988 | 130 | 0,1 mg x 2* | 6 | HAMD, CGI, Bf-S | Sedariston | 88% | Amitryptilin | 80% | 35 |
| Schilch, 1987 | 49 | 0,25 mg x 3 | 4 | HAMD | Psychotonin M | 28.4% | Placebo | -23% | 45 |
| Warnecke, 1986 | 60 | 0,3mg x 2 | 12 | HAMA, SDS, CGI | Hyperforat | 77%** | Diazepam | 50% | - |
| Steger, 1985 | 93 | 0,1 mg x 2 * | 6 | CGI, D-S, B-L | Sedariston | 70% | Desipramin | 30% | - |
| Panijel, 1985 | 100 | 0,1 mg x 2* | 2 | CGI, B-L, STAI | Sedariston | 78%** | Diazepam | 54% | - |
| Hoffmann, 1979 | 60 | 3 mg x 3 | 6 | Own Scale | Hyperforat | 61.4% | Placebo | 15.2% | 16 |
D-S = Depression Scale according to von Zerssen; CGI = Clinical Global Impression score; B-L = von Zerssen Health Compliant survey; BEB = Hänsgens complaint inventory; Bf-S = v. Zerssen´s SelfRating Scale; STAI = State Trait Anxiety Inventory ; KAI = Lehrl's Short Test on General Information processing; SAD = Seasonal Affective Disorders, SDS =Self Rating Depression Scale * = + 50 mg Valeriana in combination-medication. ** Measured by CGI *** combination medication with Hypericum, Valeria, Passiflorae, Coridalis cavae and Eschscholixiae californiae
Click Here for Index of Charts & Tables
Copyright © 1996 by Harold H. Bloomfield, M.D. and Peter McWilliams
Disclaimer - Copyright - Contact
Online: buildfreedom.org - terrorcrat.com - mind-trek.com